• Explore /
  • Poster
  • / Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.

Abstract Poster

Authors

null

Robert E. Martell

Tufts Medical Center Cancer Center, Boston, MA

Robert E. Martell , Igor Puzanov , Wen Wee Ma , Armando Santoro , Grace K. Dy , Laura Williams Goff , Gerald J. Fetterly , Shaunita A. Michael , Julie Ann Means-Powell , Feng Chai , Maria Lamar , Matteo Simonelli , Wendy M. Chiang , Jamie Jarboe , Brian E. Schwartz , Alex A. Adjei

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT00827177

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4117)

DOI

10.1200/jco.2012.30.15_suppl.4117

Abstract #

4117

Poster Bd #

50D

Abstract Disclosures

Similar Posters

First Author: Igor Puzanov

First Author: Mario E. Lacouture

First Author: A. A. Adjei

First Author: Anisha B Patel